Mink

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Retrieved on: 
Monday, April 8, 2024
TME, FAP, Cell, Immunotherapy, Colorectal cancer, Mink, Patient, Tumor microenvironment, Cancer, PST, AACR, MSS, Neoplasm, Therapy, CRC, Liver, Liver disease, Vaccine

The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.

Key Points: 
  • The data presented at AACR demonstrate MiNK-215's potential to effectively combat colorectal liver metastases, offering hope for patients who have exhausted conventional treatment options,” said Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.
  • This collaboration holds promise in bolstering the anti-tumor response, particularly in the formidable realm of microsatellite stable colorectal cancer."
  • Liver mets have limited the efficacy of immunotherapy in patients with mismatch repair proficient/microsatellite-stable (pMMR/MSS) colorectal cancer (CRC).
  • MiNK's innovative iNKT cell therapy, MiNK-215, has shown the ability to remodel the immunosuppressive tumor microenvironment within the liver.

2024 American Women Quarters Rolls and Bags™ Celebrating the Honorable Patsy Takemoto Mink on Sale March 28

Retrieved on: 
Thursday, March 21, 2024
House, Congress, American Women quarters, Portrait, EDT, TRUST, AMERICA, Mink, United States Mint, Patsy Mink, Woman, Public law, Mint, Representative, Legislation

Washington, DC, March 21, 2024 (GLOBE NEWSWIRE) -- The United States Mint (Mint) 2024 American Women Quarters rolls and bags celebrating the Honorable Patsy Takemoto Mink will be available for purchase on March 28 at noon EDT.

Key Points: 
  • Washington, DC, March 21, 2024 (GLOBE NEWSWIRE) -- The United States Mint (Mint) 2024 American Women Quarters rolls and bags celebrating the Honorable Patsy Takemoto Mink will be available for purchase on March 28 at noon EDT.
  • The American Women Quarters rolls and bags are also available for purchase through the Mint’s Subscription Program .
  • The reverse (tails) of this coin depicts the Honorable Patsy Takemoto Mink holding her landmark “TITLE IX” legislation.
  • The American Women Quarters Program is authorized by the Circulating Collectible Coin Redesign Act of 2020 (Public Law 116-330).

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

Exposed: the dark reality of profit-driven wildlife farms

Retrieved on: 
Thursday, March 14, 2024
Elephant, Congress, Farm, Pressure, Freedom of information, Disease, Amphibian, Risk, Cannibalism, Freedom, Research, Reptile, Sale, Bird, Mammal, Mink, Zoonosis, World Animal Protection, Animal, Tourism, Breeding, Profit, Injury, Pet, Cat, Parakeet, Bile, Legislation

NEW YORK, March 14, 2024 /PRNewswire/ -- Published today, World Animal Protection's new report entitled Bred for Profit: The Truth about Global Wildlife Farming reveals for the first time the vast scale of this exploitative industry. Extensive research uncovered that billions of wild animals are bred each year and suffer on wildlife farms for uses such as "pets," entertainment, tourism, hunting, fashion, luxury goods, and traditional medicine. There is an astonishing lack of transparency and inadequate monitoring across this global multi-billion-dollar industry.

Key Points: 
  • Extensive research uncovered that billions of wild animals are bred each year and suffer on wildlife farms for uses such as "pets," entertainment, tourism, hunting, fashion, luxury goods, and traditional medicine.
  • Animals held on wildlife farms suffer from malnourishment, disease, stress-induced behaviors, injuries, infected wounds—and even cannibalism.
  • Shockingly, some captive wildlife populations are now larger than those living free.
  • World Animal Protection is urging governments worldwide to take immediate action by implementing a comprehensive and timely phase out of commercial wildlife farms and associated trade.

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Retrieved on: 
Thursday, March 7, 2024
Therapy, Webcast, Mink, Cancer

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year-end 2023 financial results before the market opens on Thursday, March 21, 2024.
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • ET that morning to discuss the results and to provide a corporate update.

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Liver, ICIS, FAP, CRC, Mink, MSS, Therapy, Patient, Colorectal cancer, Liver disease, Cancer, Vaccine

MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases.

Key Points: 
  • MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases.
  • This includes the tumor antigens that present due to liver metastases, as the liver shuts down the anti-cancer T cell response.
  • Consequently, liver metastases pose a significant challenge for current pharmacological treatments, including immune checkpoint inhibitors (ICIs).
  • iNKT cells offer promise in overcoming this immune barrier, given their natural ability to reside in and migrate to the liver.

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Retrieved on: 
Wednesday, February 14, 2024
Gastrointestinal cancer, Cancer, GEJ, Mink, Stomach, GI, Therapy, Paclitaxel, Patient, Disease, Tissue, Pharmaceutical industry

The trial builds upon findings from MiNK’s recently published clinical trial ( Carneiro et al .

Key Points: 
  • The trial builds upon findings from MiNK’s recently published clinical trial ( Carneiro et al .
  • 2024 Oncogene) demonstrating that agenT-797 appears to overcome resistance to immune checkpoint inhibitors, with durable disease stabilization and a confirmed response in chemotherapy and anti-PD-1 refractory gastric cancer.
  • "AgenT-797, an off-the-shelf iNKT cell-based therapy, has shown the capacity to target cancerous cells in diseased tissues and is compatible with immune checkpoint inhibitors.
  • This study builds upon the promising outcomes observed with iNKTs in gastric cancer and with botensilimab/balstilimab in GI cancers.

Born Free USA Applauds the Introduction of Bill to End Mink Farming in Illinois; Urges Swift Passage

Retrieved on: 
Wednesday, February 7, 2024
Pandemic, State legislature (United States), COVID-19, Public, H5N1, Mortality, Human, Illinois Senate, Safety, Senate, Mink, Global health, State, Respiratory system, Health, Farm, Infection

WASHINGTON, Feb. 7, 2024 /PRNewswire/ -- Born Free USA , a leading wildlife nonprofit, applauds the introduction of Mink Facility Disease Prevention Act (S.B.

Key Points: 
  • WASHINGTON, Feb. 7, 2024 /PRNewswire/ -- Born Free USA , a leading wildlife nonprofit, applauds the introduction of Mink Facility Disease Prevention Act (S.B.
  • Sponsored by State Senate Assistant Majority Leader Linda Holmes, this bill would ban mink fur farming in the state of Illinois to protect public health.
  • Says Angela Grimes, Born Free USA CEO, "The COVID-19 pandemic has shown us that fur farming is harmful to human health and safety.
  • Born Free USA calls on the Illinois legislature to act quickly to pass the bill into law.

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Retrieved on: 
Tuesday, February 6, 2024
SARS-CoV-2, COVID-19, Mortality, Survival, Immunity, Pneumonia, VV, Nature Communications, Biomarker, Patient, Respiratory failure, Periodic breathing, Disease, Therapy, Doctor of Philosophy, University, Mink, Cancer, White lung, Survival rate, Viral pneumonia, Vaccine

These findings show that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile.

Key Points: 
  • These findings show that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile.
  • ARDS is a life-threatening, rapidly progressive form of respiratory failure, associated with approximately 40% mortality.
  • These data stand in stark contrast compared to 10% survival rate in the in-hospital control group at the same time.
  • The company plans to further advance agenT-797 in patients with viral ARDS through an externally funded, large platform trial.”
    The publication is available at: https://www.nature.com/articles/s41467-024-44905-z .

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Retrieved on: 
Tuesday, January 30, 2024
PD-L1, FOLFOX, Immune system, Division, Clinical trial, RECIST, Patient, Stomach, Therapy, ICIS, Pembrolizumab, Brown University, Nivolumab, Associate, Stomach cancer, Mink, Cancer, Clinical research, Malignancy

“Novel therapeutic approaches, like allogeneic iNKT cells, are urgently needed to overcome resistance to immune checkpoint inhibitors in gastric cancers and other refractory solid tumors.

Key Points: 
  • “Novel therapeutic approaches, like allogeneic iNKT cells, are urgently needed to overcome resistance to immune checkpoint inhibitors in gastric cancers and other refractory solid tumors.
  • The activity, tolerability, and ease of off-the-shelf administration of iNKT-based cell therapies position them as an attractive approach for overcoming cancer resistance.”
    Gastric cancer, the fifth most common malignancy globally, is incurable with only 12% responsive to ICIs1,2.
  • This phase study (NCT05108623) was designed to evaluate agenT-797, an unmodified iNKT cell therapy, in solid tumors refractory to ICIs.
  • Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer.